Is PT-141 (Bremelanotide) Legal in Minnesota?

What Is PT-141 (Bremelanotide) and Why Does Legal Status Matter?

PT-141 is the research name for bremelanotide, a cyclic heptapeptide that acts on melanocortin receptors MC3R and MC4R in the central nervous system to increase sexual desire. Unlike sildenafil or tadalafil, it does not work through vascular mechanisms. The FDA approved it in June 2019 under the brand name Vyleesi for acquired, generalized HSDD in premenopausal women. [1]

Legal status matters because the drug exists in two very different regulatory contexts: a fully FDA-approved brand product and a compounded peptide with a contested status. Patients and clinicians who understand both contexts can make lawful, informed access decisions.

The Difference Between Brand and Compounded Bremelanotide

Vyleesi (brand bremelanotide) is an FDA-approved new drug application (NDA) product manufactured by AMAG Pharmaceuticals. It carries a full prescribing label, safety data, and insurance billing codes. Any licensed Minnesota prescriber can write for it, and any licensed Minnesota pharmacy can dispense it. [2]

Compounded bremelanotide is a different matter. Compounding pharmacies can prepare custom formulations under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) when a prescriber identifies a patient-specific clinical need. However, the FDA's 503A bulk-drug substance nominee process evaluates whether a compound is appropriate for pharmacy compounding without an approved NDA, and bremelanotide was not placed on the positive list. [3]

Why the 2022 FDA Nominee Decision Changed the Field

Before 2022, compounding pharmacies operated in a gray zone with bremelanotide. The FDA's final decision declining to include bremelanotide on the 503A bulks list narrowed that space considerably. Compounders who continue preparing bremelanotide do so outside explicit FDA authorization for bulk-drug compounding, which exposes both pharmacy and prescriber to regulatory risk. [4]

The FDA has stated explicitly in its compounding guidance documents that a drug with an approved NDA is generally not a candidate for compounding unless the patient has a documented medical need that cannot be met by the commercial product (e.g., an allergy to an inactive ingredient). [5]

Federal Legal Framework for Bremelanotide

FDA Approval and NDA Status

The FDA approved bremelanotide on June 21, 2019 (NDA 210557) following two key phase 3 trials (RECONNECT trials, combined N=1,267). In those trials, bremelanotide 1.75 mg subcutaneous produced statistically significant improvements in the Female Sexual Function Index desire domain score compared to placebo (P<0.001) at 24 weeks. [6]

The approved indication is specific: acquired, generalized HSDD in premenopausal women. Use outside this indication (such as in postmenopausal women or men) is off-label and requires additional clinical documentation, though off-label prescribing is legal under U.S. Medical practice law. [7]

Controlled Substance Status Under Federal Law

Bremelanotide is not scheduled under the federal Controlled Substances Act (CSA). The Drug Enforcement Administration (DEA) has not placed it in Schedules I through V. This means prescriptions do not require DEA-mandated triplicate forms, DEA registration is not triggered by prescribing it, and patients face no federal criminal exposure for lawful possession under a valid prescription. [8]

Compounding Under 503A vs. 503B

Two compounding pathways exist under federal law:

• 503A pharmacies serve individual patients on a prescription-by-prescription basis. They may use bulk drug substances only from the FDA's approved bulks list or the interim bulks list. Bremelanotide is on neither. A 503A pharmacy compounding bremelanotide is operating outside FDA-authorized parameters unless a specific exemption applies. [3]
• 503B outsourcing facilities may compound drugs not on the approved-drug list only under very specific shortage or clinical-need criteria. No active FDA shortage designation exists for Vyleesi. A 503B compounding bremelanotide for routine HSDD use is almost certainly outside authorized scope. [9]

The FDA's Office of Pharmaceutical Quality publishes inspectional observations for compounders who prepare unapproved bulk substances. Clinicians prescribing compounded bremelanotide should request a certificate of analysis and documentation of the pharmacy's legal basis for compounding. [10]

Minnesota State Law and Bremelanotide

Minnesota Does Not Separately Schedule Bremelanotide

Minnesota maintains its own controlled-substance schedules under Minn. Stat. § 152.02. Bremelanotide does not appear on any Minnesota schedule. Minnesota generally mirrors federal scheduling, so the absence of a federal schedule means no state-level scheduling either. Possession and use under a valid Minnesota prescription carry no state criminal liability. [11]

Minnesota Board of Pharmacy Rules on Compounding

The Minnesota Board of Pharmacy regulates compounding under Minn. Rules ch. 6800. Minnesota-licensed pharmacies must comply with both state board rules and federal FD&C Act compounding provisions. Because the FDA has not authorized bulk-drug compounding of bremelanotide under 503A, a Minnesota-licensed 503A pharmacy offering compounded bremelanotide is potentially operating outside both federal and state-consistent standards. [12]

The Minnesota Board of Pharmacy has not issued a specific advisory opinion on bremelanotide compounding as of the date of this review, but its general guidance directs pharmacies to comply with FDA bulks-list requirements. Patients who encounter a compounding pharmacy offering bremelanotide without a documented clinical justification should ask for written documentation of legal basis.

Minnesota Medical Practice Act and Off-Label Prescribing

Under Minn. Stat. § 147.091, the Minnesota Board of Medical Practice governs prescribing standards. Off-label prescribing of FDA-approved drugs is explicitly permissible and does not constitute unprofessional conduct when supported by clinical evidence. [13] A Minnesota physician prescribing brand Vyleesi off-label (for example, for a postmenopausal woman with HSDD) is operating within the bounds of Minnesota medical practice law as long as the decision is documented and evidence-based.

How to Get PT-141 (Bremelanotide) Legally in Minnesota

Step 1, Establish Care With a Licensed Minnesota Prescriber

A Minnesota-licensed physician, nurse practitioner, or physician assistant may prescribe bremelanotide. Telehealth prescribing is legal in Minnesota for established patient-provider relationships following the state's telehealth parity law (Minn. Stat. § 62A.673). [14] This means a video or synchronous audio consultation with a Minnesota-licensed provider satisfies the prescribing encounter requirement.

A thorough clinical evaluation should include:

• Confirmation of HSDD diagnosis using validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R)
• Baseline cardiovascular assessment given the drug's transient blood-pressure effect
• Medication reconciliation to check for contraindicated drugs
• Review of thyroid and hormonal status, as low estrogen or androgen levels can independently cause low desire

Step 2, Obtain a Valid Prescription for Brand Vyleesi

Brand Vyleesi is the legally unambiguous option. The prescriber transmits an electronic prescription to any Minnesota-licensed retail or specialty pharmacy. Major pharmacy benefit managers cover Vyleesi under some commercial plans; prior authorization is common. Manufacturer savings programs may reduce out-of-pocket cost for commercially insured patients. [1]

Step 3, If Compounded Bremelanotide Is Recommended, Verify the Pharmacy's Legal Basis

Some telehealth platforms continue to offer compounded bremelanotide despite the FDA bulks-list decision. If a clinician recommends this route, patients should request:

1. Written documentation that the pharmacy is a licensed 503A pharmacy in good standing with the Minnesota Board of Pharmacy.
2. A certificate of analysis from an accredited third-party laboratory confirming identity, potency, and sterility of the compounded product.
3. A written clinical justification explaining why the commercial Vyleesi product cannot meet the patient's specific need.

Without these three documents, accessing compounded bremelanotide carries regulatory and safety risk that patients deserve to understand before proceeding. [5]

Step 4, Self-Administration and Storage

Vyleesi is supplied as a 1.75 mg/0.3 mL single-dose auto-injector for subcutaneous injection into the abdomen or thigh. Patients self-administer 45 minutes before anticipated sexual activity. No more than one dose per 24 hours is recommended. The device should be stored at room temperature below 77 degrees Fahrenheit and protected from light. [1]

Clinical Evidence Supporting Bremelanotide Use

The RECONNECT Phase 3 Trials

The key evidence base for bremelanotide comes from two identically designed phase 3 randomized controlled trials (Study 301 and Study 302, collectively called RECONNECT) published in Obstetrics and Gynecology in 2019 (combined N=1,267 premenopausal women with HSDD). [6]

Participants receiving bremelanotide 1.75 mg subcutaneous showed:

• A statistically significant increase in the number of satisfying sexual events compared to placebo at 24 weeks (P<0.001)
• A statistically significant reduction in FSDS-R score (distress) compared to placebo (P<0.001)
• Nausea in approximately 40% of treated patients, typically mild to moderate and resolving within 2 hours

The trials enrolled only premenopausal women with acquired, generalized HSDD, which is why the approved label is restricted to this population. [6]

Melanocortin Receptor Pharmacology

Bremelanotide binds MC3R and MC4R receptors in the hypothalamus and limbic system. A 2014 pharmacology review in the Journal of Sexual Medicine described bremelanotide's central mechanism as distinct from peripheral vasodilators, noting activation of dopaminergic and oxytocin-mediated pathways that may account for its pro-desire effect. [15]

A 2016 phase 2 dose-finding trial (N=395) published in the Journal of Sexual Medicine established the 1.75 mg subcutaneous dose as the optimal balance of efficacy and tolerability before the RECONNECT phase 3 program was initiated. [16]

Cardiovascular Safety Signals

The FDA prescribing label carries a warning regarding transient blood pressure changes. In the RECONNECT trials, bremelanotide produced a mean maximum decrease in systolic blood pressure of approximately 6 mmHg and a mean maximum increase in diastolic blood pressure of approximately 3 mmHg within 12 hours of dosing. [1] Patients with cardiovascular disease, uncontrolled hypertension, or a history of cardiac events were excluded from the key trials and are listed as a contraindication in the label.

The FDA's Adverse Event Reporting System (FAERS) contains post-marketing reports of more pronounced blood-pressure changes in patients outside the studied population, reinforcing the importance of cardiovascular screening before prescribing. [17]

Who Is a Candidate for Bremelanotide?

Approved Indication

The FDA-approved population is premenopausal women with acquired, generalized HSDD. "Acquired" means the disorder developed after a period of normal sexual desire. "Generalized" means it occurs across all sexual contexts and partners. Both criteria must be present for the labeled indication. [1]

Off-Label Use in Postmenopausal Women

Some clinicians prescribe bremelanotide off-label for postmenopausal women, though estrogen deficiency and androgen decline should be addressed first. The Menopause Society (formerly NAMS) 2022 position statement on female sexual dysfunction notes that hormone therapy may restore desire in postmenopausal women and recommends evaluating hormonal status before adding a centrally acting agent. [18]

Use in Men: Evidence and Legal Status

Bremelanotide has been studied in men with erectile dysfunction and was investigated under the name PT-141 in early-phase trials. A 2008 phase 2 trial published in the Journal of Sexual Medicine (N=78) found intranasal bremelanotide produced erections in men with psychogenic erectile dysfunction, but the FDA did not approve this indication, and AMAG did not pursue NDA approval for men. [19]

Prescribing bremelanotide to men is therefore off-label. It is not illegal under Minnesota or federal law, but the clinical evidence base is significantly thinner than for approved HSDD use in women, and the prescriber assumes greater professional responsibility for documentation and informed consent.

The table below provides a decision framework for Minnesota clinicians evaluating bremelanotide access paths:

| Clinical scenario | Recommended access path | Legal risk level | |---|---|---| | Premenopausal woman, confirmed HSDD, no CV disease | Brand Vyleesi via retail Rx | Minimal | | Premenopausal woman, allergy to Vyleesi excipient | Compounded bremelanotide with documented justification | Low if properly documented | | Postmenopausal woman, hormones optimized, persistent HSDD | Off-label brand Vyleesi with documented rationale | Low | | Man with psychogenic ED, sildenafil not tolerated | Off-label brand Vyleesi; document thin evidence base | Moderate (off-label, limited evidence) | | Any patient, compounded form without documented justification | Not recommended | High |

Drug Interactions and Contraindications Relevant to Minnesota Prescribers

Bremelanotide's prescribing label identifies naltrexone and indomethacin as drugs that may reduce efficacy through pharmacodynamic antagonism. High-dose naltrexone used in medication-assisted treatment for opioid use disorder (a common co-prescription in Minnesota clinical practice) may blunt bremelanotide's effect. [1]

Patients taking naltrexone for alcohol use disorder at the 50 mg oral daily dose commonly used in Minnesota primary care and addiction medicine settings should have a frank discussion with their prescriber about whether concurrent bremelanotide use is clinically reasonable. [20]

The label also flags melanoma risk: because bremelanotide stimulates melanocortin receptors, it should not be used in patients with a history of melanoma or undiagnosed pigmented lesions. A dermatologic review before prescribing is appropriate in patients with a personal or family history of melanoma. [1]

Telehealth Access to Bremelanotide in Minnesota

Minnesota's telehealth parity law (Minn. Stat. § 62A.673) requires insurers to cover telehealth services equivalent to in-person services. A synchronous video consultation with a Minnesota-licensed prescriber satisfies the clinical encounter requirement for prescribing Vyleesi. [14]

Telehealth platforms that prescribe compounded bremelanotide without first offering brand Vyleesi or documenting a patient-specific reason to compound are operating in a legally exposed space. Patients using telehealth should confirm:

• The prescribing clinician holds an active Minnesota license
• The prescription is being sent to a pharmacy licensed in Minnesota
• The product offered is brand Vyleesi or, if compounded, accompanied by appropriate documentation

The Minnesota Department of Health published telehealth guidance in 2023 confirming that prescribing standards (including appropriate clinical evaluation) apply equally to telehealth encounters. Prescribers cannot rely on patient self-reported diagnosis alone to justify a bremelanotide prescription. [21]